Work

Preclinical radiation dose optimization, dosimetry and maximum tolerated dose studies of Lu-177-labeled CTT1403, a phosphoramidate-based PSMA inhibitor for targeted radionuclide therapy of prostate cancer.

Year: 2018

Type: article

Source: Journal of Nuclear Medicine

Authors: Xiaoxi Ling, Joseph D. Latoche, Cindy J. Choy, Jonathan J. Geruntho, Charles M. Laymon, Brenda F. Kurland, Beatrice Langton-Webster, Clifford E. Berkman, Carolyn J. Anderson

Institutions: University of Pittsburgh, Cancer Targeted Technology (United States)

Language: English

Topic: Radiopharmaceutical Chemistry and Applications

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2902050182

FWCI:

Cites:

Cited by:

Related to: 10